TickerGuard
Buy Day today: Good (67) Broad market participation · no major macro event

Ultragenyx (RARE)

Healthcare Biotechnology
25.00 $
+0.4% vs. previous close
Closing price · As of: 3. Aug 2026

Ultragenyx (RARE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Revenue" came in at 673 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Income Statement RARE
Tick rows to compare them in a chart (up to 4) 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
0.0 0.0 0.1 2.6 51 104 271 351 363 434 560 673
0.0 1.4 183 0.0 1.1 9.0 6.1 16 28 45 77 109
0.0 -1.4 0.1 2.6 50 95 265 335 335 389 484 564
46 115 183 232 294 357 412 497 706 648 698 750
11 33 65 100 128 162 183 220 278 310 322 349
57 148 248 332 422 519 595 717 984 958 1,019 1,099
-57 -148 -248 -329 -371 -424 -330 -382 -649 -569 -536 -535
0.0 0.0 0.0 0.0 0.0 1.1 33 29 43 66 63 62
-60 -146 -246 -318 -197 -399 -185 -453 -702 -608 -568 -571
-0.7 -2.3 0.0 -16 0.5 3.3 1.2 1.0 5.7 -1.8 1.6 4.0
-60 -146 -246 -302 -198 -403 -187 -454 -707 -607 -569 -575
-56 -146 -245 -323 -178 -390 -140 -410 -640 -516 -469 -474

Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?